Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HE 3235

Drug Profile

HE 3235

Alternative Names: Apoptone; HE-3235

Latest Information Update: 29 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hollis-Eden Pharmaceuticals
  • Developer Harbor Therapeutics
  • Class Androstanols; Antineoplastics; Hormonal steroids; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Apoptosis stimulants; Raf kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 29 Sep 2015 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Late-stage disease, Treatment-experienced) in USA (PO)
  • 29 Sep 2015 Discontinued - Preclinical for Breast cancer in USA (PO)
  • 28 Feb 2011 Pharmacodynamics data from animal studies in breast cancer released by Harbor BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top